Product name:
PSMA I&T
Precursor for radiometal-labelled PSMA I&T
For imaging and radionuclide therapy of prostate cancer.
Molecular Weight:
1498.37 [g/mol]
Molecular Formula:
C63H92IN11O23
*Delivery time: On stock
General Information
| Product no.: | 50158 |
| Product name: | PSMA I&T |
| Sequence: | D-Lysine, N-[4-carboxy-1-oxo-4- [4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-3-iodo- D-tyrosyl-D-phenylalanyl-N6-[8-[[(5S)-5-carboxy-5-[[[[(1S)-1,3-dicarboxypropyl]amino] carbonyl]amino]pentyl]amino]-1,8-dioxooctyl] |
| Molecular weight: | 1498.37 [g/mol] |
| Molecular formula: | C63H92IN11O23 |
| CAS no.: | 2192281-54-0 |
Product Description
Labelling precursor for [68Ga], [177Lu] and [225Ac].
For use by qualified personnel only.
Not for drug use. For laboratory use only.
Quantity
Product No. 50158: 1000 µg net peptide
Packaging
2 mL Cryovials
Storage and Stability
Storage at -20°C, sealed, away from moisture and protected from light.
Certificates
Certificate of Analysis
Product Data Sheet
Literature
[1] Weineisen M. et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med, 2015, 56(8):1169-76.
[2] Fendler WP. et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.Eur J Nucl Med Mol Imaging, 2017, 44(6):1014-1024.
[3] Kulkarni HR et al. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. J Nucl Med. 2016, 57(Suppl 3):97S-104S.
[4] von Eyben FE. et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging, 2018, 45(3):496-508.
[5] Chatalic KL, et al. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics. 2016 Apr 12;6(6):849-6.
